Drug Trial Radar · NCT06748053
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
307
Actual
Start
Feb 10, 2025
Primary completion
Jul 14, 2026
Study completion Sep 9, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Dec 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is trying to find the right dose of a long-lasting medicine called GSK5784283 for people with asthma that remains uncontrolled even though they are using regular asthma treatments. GSK5784283 blocks the action of an inflammatory protein called TSLP that may be contributing to your asthma. The study will be conducted in two parts - Part A (dose finding phase) and Part B (extended dosing phase). Part A will assess the lung function, asthma control, participant safety and certain markers of asthma inflammation in the air you breath out and in your blood. Part B will assess the safety and long-term effects of the repeated or single doses of GSK5784283.
Conditions
- Asthma
Interventions
GSK5784283Drug
GSK5784283 will be administered.
PlaceboDrug
Placebo will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Change from baseline in the fraction of exhaled nitric oxide (FeNo)Time frame: Baseline (Day 1) and at 2, 4, 8,12, 20 and 26 weeks
Locations
137 sites in 9 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Modesto, California
GSK Investigational Site
Redding, California
GSK Investigational Site
Riverside, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
San Jose, California
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
Lakewood, Colorado
GSK Investigational Site
Wheat Ridge, Colorado
GSK Investigational Site
New Haven, Connecticut
GSK Investigational Site
Aventura, Florida
GSK Investigational Site
Hialeah, Florida
GSK Investigational Site
Lake Worth, Florida
GSK Investigational Site
Leesburg, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Plantation, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Skokie, Illinois
GSK Investigational Site
Shreveport, Louisiana
GSK Investigational Site
Lathrup Village, Michigan
GSK Investigational Site
Warren, Michigan
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
The Bronx, New York
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
DuBois, Pennsylvania
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Wyomissing, Pennsylvania
GSK Investigational Site
Warwick, Rhode Island
GSK Investigational Site
Greenville, South Carolina
GSK Investigational Site
Spartanburg, South Carolina
GSK Investigational Site
Knoxville, Tennessee
GSK Investigational Site
Boerne, Texas
Showing 40 of 137 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.